These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 9663835

  • 1. Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole.
    Hatlebakk JG, Berstad A.
    Aliment Pharmacol Ther; 1997 Dec; 11(6):1093-9. PubMed ID: 9663835
    [Abstract] [Full Text] [Related]

  • 2. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole.
    Mee AS, Rowley JL.
    Aliment Pharmacol Ther; 1996 Oct; 10(5):757-63. PubMed ID: 8899084
    [Abstract] [Full Text] [Related]

  • 3. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood.
    Franco MT, Salvia G, Terrin G, Spadaro R, De Rosa I, Iula VD, Cucchiara S.
    Dig Liver Dis; 2000 Nov; 32(8):660-6. PubMed ID: 11142573
    [Abstract] [Full Text] [Related]

  • 4. Lansoprazole for maintenance of remission of erosive oesophagitis.
    Freston JW, Jackson RL, Huang B, Ballard ED.
    Drugs; 2002 Nov; 62(8):1173-84. PubMed ID: 12010078
    [Abstract] [Full Text] [Related]

  • 5. A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis.
    Jaspersen D, Diehl KL, Schoeppner H, Geyer P, Martens E.
    Aliment Pharmacol Ther; 1998 Jan; 12(1):49-52. PubMed ID: 9692700
    [Abstract] [Full Text] [Related]

  • 6. Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis.
    Hatlebakk JG, Berstad A.
    Aliment Pharmacol Ther; 1997 Apr; 11(2):365-72. PubMed ID: 9146777
    [Abstract] [Full Text] [Related]

  • 7. Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis.
    Netzer P, Gut A, Brundler R, Gaia C, Halter F, Inauen W.
    Aliment Pharmacol Ther; 2001 Sep; 15(9):1375-84. PubMed ID: 11552908
    [Abstract] [Full Text] [Related]

  • 8. Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis.
    Newton M, Burnham WR, Kamm MA.
    Eur J Gastroenterol Hepatol; 1998 Sep; 10(9):753-8. PubMed ID: 9831269
    [Abstract] [Full Text] [Related]

  • 9. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
    Scott LJ, Dunn CJ, Mallarkey G, Sharpe M.
    Drugs; 2002 Sep; 62(7):1091-118. PubMed ID: 11985491
    [Abstract] [Full Text] [Related]

  • 10. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial.
    Schwizer W, Thumshirn M, Dent J, Guldenschuh I, Menne D, Cathomas G, Fried M.
    Lancet; 2001 Jun 02; 357(9270):1738-42. PubMed ID: 11403809
    [Abstract] [Full Text] [Related]

  • 11. Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.
    Langtry HD, Wilde MI.
    Drugs; 1998 Sep 02; 56(3):447-86. PubMed ID: 9777317
    [Abstract] [Full Text] [Related]

  • 12. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
    Giral A, Celikel CA, Ozdogan O, Tözün N, Ulusoy NB, Kalayci C.
    J Gastroenterol Hepatol; 2005 Dec 02; 20(12):1886-91. PubMed ID: 16336449
    [Abstract] [Full Text] [Related]

  • 13. Long-term clinical outcome of elderly patients with reflux esophagitis: a six-month to three-year follow-up study.
    Pilotto A, Franceschi M, Leandro G, Novello R, Di Mario F, Valerio G.
    Am J Ther; 2002 Dec 02; 9(4):295-300. PubMed ID: 12115018
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism.
    Kawamura M, Ohara S, Koike T, Iijima K, Suzuki J, Kayaba S, Noguchi K, Hamada S, Noguchi M, Shimosegawa T, Study Group of GERD.
    Aliment Pharmacol Ther; 2003 Apr 01; 17(7):965-73. PubMed ID: 12656699
    [Abstract] [Full Text] [Related]

  • 16. Esomeprazole: a review of its use in the management of acid-related disorders.
    Scott LJ, Dunn CJ, Mallarkey G, Sharpe M.
    Drugs; 2002 Apr 01; 62(10):1503-38. PubMed ID: 12093317
    [Abstract] [Full Text] [Related]

  • 17. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
    Langtry HD, Wilde MI.
    Drugs; 1997 Sep 01; 54(3):473-500. PubMed ID: 9279507
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease.
    Janczewska I, Sagar M, Sjöstedt S, Hammarlund B, Iwarzon M, Seensalu R.
    Scand J Gastroenterol; 1998 Dec 01; 33(12):1239-43. PubMed ID: 9930385
    [Abstract] [Full Text] [Related]

  • 19. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole.
    Berstad AE, Hatlebakk JG, Maartmann-Moe H, Berstad A, Brandtzaeg P.
    Gut; 1997 Dec 01; 41(6):740-7. PubMed ID: 9462205
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children.
    Tolia V, Ferry G, Gunasekaran T, Huang B, Keith R, Book L.
    J Pediatr Gastroenterol Nutr; 2002 Dec 01; 35 Suppl 4():S308-18. PubMed ID: 12607791
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.